Combination Therapy with Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis Induced Clinical Remission in a Crohn's Disease Patient with the Loss of Response to Scheduled Adalimumab Maintenance Therapy: A Case Report

被引：8
|
作者：
Ozeki, Keiji [1 ]
Tanida, Satoshi [1 ]
Mizushima, Takashi [2 ]
Mizoshita, Tsutomu [1 ]
Tsukamoto, Hironobu [1 ]
Hirata, Yoshikazu [1 ]
Murakami, Kenji [1 ]
Shimura, Takaya [1 ]
Kataoka, Hiromi [1 ]
Kamiya, Takeshi [1 ]
Joh, Takashi [1 ]
机构：
[1] Nagoya City Univ, Grad Sch Med Sci, Dept Gastroenterol & Metab, Nagoya, Aichi, Japan
[2] Gifu Prefectural Tajimi Hosp, Gifu, Japan
来源：
INTERNAL MEDICINE | 2012年 / 51卷 / 06期
关键词：
refractory Crohn's disease; adalimumab; intensive granulocyte/monocyte adsorptive apheresis; anti-adalimumab antibody; clinical remission; INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; NECROSIS-FACTOR; TRIAL; MULTICENTER; INFECTION;
D O I：
10.2169/internalmedicine.51.6801
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A 21-year-old Caucasian man with a diagnosis of Crohn's disease (CD) at the age of 14 was admitted to our hospital due to CD flare-up while under scheduled adalimumab (ADA) maintenance therapy. His symptoms remained virtually unchanged following high dose corticosteroid therapy. Seven days later, combination therapy with ADA plus intensive granulocyte/monocyte adsorptive apheresis (GMA) was initiated, which induced clinical remission. Therefore, combination therapy with ADA plus intensive GMA appears to be an effective therapeutic option for patients with severe CD while under scheduled ADA maintenance therapy.
引用
收藏
页码：595 / 599
页数：5
相关论文
共 50 条
  • [41] Comparative study of infliximab and adalimumab induction therapy for clinical remission and mucosal healing in paediatric patients with active Crohn's disease
    Szymanska, E.
    Dadalski, M.
    Szymanska, S.
    Grajkowska, W.
    Pronicki, M.
    Jaroslaw, K.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S290 - S290
  • [42] Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
    Suzuki, Taketo
    Mizoshita, Tsutomu
    Sugiyama, Tomoya
    Hirata, Yoshikazu
    Kimura, Yoshihide
    Suzuki, Yuka
    Yamada, Tomonori
    Tsukamoto, Hironobu
    Mizushima, Takashi
    Sugimura, Naomi
    Katano, Takahito
    Tanida, Satoshi
    Kataoka, Hiromi
    Sasaki, Makoto
    CASE REPORTS IN GASTROENTEROLOGY, 2019, 13 (01) : 37 - 49
  • [43] Does Combination Therapy using Rifaximin with Adalimumab improve Crohn's Disease activity and Mucosal Healing? A Case Series
    Shafran, I
    Burgunder, P.
    INFLAMMATORY BOWEL DISEASES, 2009, 15 (12) : S9 - S10
  • [44] Impact of adalimumab maintenance therapy on patient-reported outcomes among patients with fistulising Crohn's disease in the charm trial
    Colombel, J. F.
    Loftus, E. V.
    Feagan, B. G.
    Schwartz, D. A.
    Wu, E. Q.
    Yu, A.
    Pollack, P. F.
    Chao, J.
    Mulani, P.
    GUT, 2008, 57 : A116 - A116
  • [45] Successful closure of ileostomy in a patient with intestinal Behcet's disease after therapy with adalimumab A case report
    Yan, Zhe
    Cui, Bei-Bei
    Yu, Yong-Yang
    Yin, Geng
    Cen, Xiao-Min
    Xie, Qi-Bing
    MEDICINE, 2019, 98 (09)
  • [46] Rapid induction of remission and clinical response with adalimumab in patients with moderate to severe Crohn's disease and secondary failure to infliximab therapy: Results of the gain studya
    Columbel, J.
    Rutgeerts, P.
    Sandborn, W. J.
    Enns, R.
    Hanauer, S. B.
    Kent, J. D.
    Pollack, P. F.
    GUT, 2007, 56 : A109 - A109
  • [47] Concomitant Elemental Diet Therapy Is Effective in Sustaining Infliximab Scheduled Maintenance Therapy in Patients With Crohn's Disease to Prevent Loss of Response
    Kamata, Noriko
    Watanabe, Kenji
    Tsukahara, Takuya
    Hagihara, Yoshie
    Morimoto, Kenichi
    Noguchi, Atsushi
    Miyazaki, Takako
    Sogawa, Mitsue
    Yamagami, Hirokazu
    Tanigawa, Tetsuya
    Shiba, Masatsugu
    Watanabe, Toshio
    Tominaga, Kazunari
    Fujiwara, Yasuhiro
    Arakawa, Tetsuo
    GASTROENTEROLOGY, 2013, 144 (05) : S433 - S433
  • [48] Predictors of clinical response during adalimumab therapy in Crohn's disease patients: a German non-interventional study
    Blumenstein, I.
    Atreya, R.
    Greger, G.
    Bokemeyer, B.
    Nurwakagari, P.
    Neurath, M. F.
    Wittig, B.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S146 - S146
  • [49] Pityriasis Lichenoides Chronica Induced by Adalimumab Therapy for Crohn's Disease: Report of 2 Cases Successfully Treated with Methotrexate
    Ben Said, B.
    Kanitakis, J.
    Graber, I.
    Nicolas, J. F.
    Saurin, J. C.
    Berard, F.
    INFLAMMATORY BOWEL DISEASES, 2010, 16 (06) : 912 - 913
  • [50] Sustained clinical remission in patients with moderate to severe Crohn's disease with adalimumab, regardless of anti-TNF history or concomitant immunosuppressant therapy
    Hanauer, Stephen B.
    D'Haens, G. R.
    Colombel, J. F.
    Sandborn, W. J.
    Rutgeerts, P.
    Kent, J. D.
    Pollack, P. F.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S457 - S457
12345